NASDAQ:PRAN - Prana Biotechnology Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prana Biotechnology Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.71 +0.03 (+4.41 %) (As of 02/20/2020 06:09 AM ET) Add Compare Today's Range$0.66Now: $0.71▼$0.7150-Day Range$0.95MA: $1.41▼$2.0652-Week Range$1.09Now: $0.71▼$2.91Volume10,966 shsAverage Volume130,956 shsMarket Capitalization$6.32 millionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAN Previous Symbol CUSIPN/A CIK1131343 Webhttp://www.pranabio.com/ Phone61-3-9349-4906Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales42.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book0.51Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares8,900,000Market Cap$6.32 million Next Earnings DateN/A OptionableNot Optionable Receive PRAN News and Ratings via Email Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions What is Prana Biotechnology's stock symbol? Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN." Has Prana Biotechnology been receiving favorable news coverage? Media stories about PRAN stock have trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prana Biotechnology earned a news sentiment score of -4.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Prana Biotechnology. Who are some of Prana Biotechnology's key competitors? Some companies that are related to Prana Biotechnology include Entasis Therapeutics (ETTX), Chembio Diagnostics (CEMI), Trevena (TRVN), Eyenovia (EYEN), Cumberland Pharmaceuticals (CPIX), ASLAN PHARMACEU/ADR (ASLN), Onconova Therapeutics (ONTX), Catabasis Pharmaceuticals (CATB), CNS Pharmaceuticals (CNSP), DiaMedica Therapeutics (DMAC), Advaxis (ADXS), Tiziana Life Sciences (TLSA), Q BioMed (QBIO), NewLink Genetics (NLNK) and Alpine Immune Sciences (ALPN). What other stocks do shareholders of Prana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prana Biotechnology investors own include NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Conatus Pharmaceuticals (CNAT), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Madrigal Pharmaceuticals (MDGL), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH). Who are Prana Biotechnology's key executives? Prana Biotechnology's management team includes the folowing people: Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)Ms. Kathryn Andrews, Chief Financial Officer (Age 52)Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory BoardDr. Steven D. Targum M.D., Chief Medical Advisor What is Prana Biotechnology's stock price today? One share of PRAN stock can currently be purchased for approximately $0.71. How big of a company is Prana Biotechnology? Prana Biotechnology has a market capitalization of $6.32 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe.View Additional Information About Prana Biotechnology. What is Prana Biotechnology's official website? The official website for Prana Biotechnology is http://www.pranabio.com/. How can I contact Prana Biotechnology? Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected] MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 182 (Thanks for Voting!)Underperform Votes: 262 (Thanks for Voting!)Total Votes: 444MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: Are sell-side analysts objective?